Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03695198 | A Study of LY3361237 in Healthy Participants | PHASE1 | COMPLETED | 64 | — | — | Oct 26, 2018 | Aug 29, 2019 | Sep 4, 2019 | 1 | United States |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3361237 - Subcutaneous (SC) | EXPERIMENTAL | LY3361237 administered SC |
| Placebo - SC | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3361237 - Intravenous (IV) | EXPERIMENTAL | LY3361237 administered IV |
| Placebo - IV | PLACEBO_COMPARATOR | Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY3361237 - SC | DRUG | LY3361237 administered SC |
| LY3361237 - IV | DRUG | LY3361237 administered IV |
| Placebo - SC | DRUG | Placebo administered SC |
| Placebo - IV | DRUG | Placebo administered IV |
Inclusion Criteria: * Healthy males or females, as determined by medical history and physical examination. * To qualify as Japanese for this study, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and b...